Harm Reduction Services

Part of paid clinical trials in New Haven, Connecticut.

Sponsor
NYU Langone Health
Study ID
NCT05776316
Status
Recruiting
Apply to this trial

Conditions

  • Drug Use
  • Mental Illness
  • Substance Abuse

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Integrated Harm Reduction Intervention (IHRI) — BEHAVIORAL
    8-week program targeting areas rooted in the 8 principles of harm reduction. Includes weekly education lessons and informed referrals to social service organizations.

Study Details

The purpose of this study is to assess whether an integrated harm reduction intervention (IHRI), compared to harm reduction (HR) services as usual, will improve harm reduction service utilization among Black and Latinx people who use drugs (PWUD).

Key Dates

Start date
Nov 25, 2024
Status verified
Mar 2026
Primary completion
Sep 29, 2026
Completion
Mar 28, 2028

Study Design

Enrollment
200 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH

Arms

  • Experimental: IHRI
    Integrated harm reduction intervention (IHRI) program tailored specifically for highly marginalized Black and Latinx people who use drugs (PWUDs). The IHRI lasts 8 weeks in duration, with the first 4 weeks consisting of weekly education lessons provided by the IHRI care coordinator. The subsequent 4 weeks will involve individualized identification of vulnerabilities in the social determinants of health (SDOH) for the purposes of making informed referrals to relevant partnering social service organizations. Participants will also be exposed to service encounters through mobile vans in which staff offer information to PWUD on syringe exchange, clean user kits, naloxone use, and fentanyl strip distribution.
  • No Intervention: HR SAU
    Harm reduction services as usual (HR SAU). Participants will be exposed to service encounters through the mobile vans in which staff offer information to PWUD on syringe exchange, clean user kits, naloxone use, and fentanyl strip distribution.

Primary Outcome Measure

Percentage of Participants who Attend At least 1 Harm Reduction (HR) Session after Introductory HR Session [ Time Frame: Up to Week 8 ]

Central Contacts

Locations (3)

FacilityCityStateZIPSite coordinators
Yale UniversityNew HavenConnecticut06520
Kimberly Sue, MD (PRINCIPAL_INVESTIGATOR)
NYU Langone HealthNew YorkNew York10016
Ayana Jordan, MD, PhD
[email protected]
Nathan Kline InstituteOrangeburgNew York10962
Ayana Jordan, MD, PhD (PRINCIPAL_INVESTIGATOR)

Find similar trials in New Haven, CT

By research site
Yale University· New Haven, CTNYU Langone Health· New York, NYNathan Kline Institute· Orangeburg, NY

Related Studies